Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Journal of Hematology & Oncology

Jorge E. Cortes¹  Pau Montesinos²  Hervé Dombret³  Sergio A. Giralt⁴  Eunice S. Wang⁵  Adriano Venditti⁶  Christoph Röllig⁷  Marcos de Lima⁸  Elihu H. Estey⁹ 

[1] Georgia Cancer Center, 1410 Laney Walker Road, CN2116, 30912, Augusta, GA, USA;Hospital Universitari I Politècnic La Fe, Valencia, Spain;CIBERONC, Instituto de Salud Carlos III, Madrid, Spain;Hôpital Saint-Louis, Université Paris, Paris, France;Memorial Sloan Kettering Cancer Center, New York, NY, USA;Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA;Tor Vergata University of Rome, Rome, Italy;University Hospital Carl Gustav Carus, Dresden, Germany;University Hospitals Seidman Cancer Center, Cleveland, OH, USA;University of Washington, Seattle, WA, USA;

关键词: Acute myeloid leukemia;    Adverse events;    Gemtuzumab ozogamicin;    Treatment management;    VOD/SOS;   

DOI  :  10.1186/s13045-020-00975-2

来源: Springer

【 摘 要 】

Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years old. GO treatment has been associated with an increased risk of hepatotoxicity and hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), especially following hematopoietic stem cell transplantation. Other non-specific serious adverse events (SAEs) associated with GO treatment are myelosuppression, bleeding/thrombocytopenia, infusion-related reaction, and tumor lysis syndrome. This report summarizes an expert panel of physicians’ recommendations for the evaluation and management of SAEs following GO, emphasizing the prevention and management of VOD/SOS.

【 授权许可】

CC BY